A FEASIBILITY STUDY OF PERIOPERATIVE VITAMIN D SUPPLEMENTATION IN PATIENTS UNDERGOING COLORECTAL CANCER RESECTION

3

| 1 | Authors DC | Vouchon Show ^{1,2} | IED | 1,2 ID | Plackmur ^{1,2} | A Ewing | ^{1,2} E |
|---|---------------|-----------------------------|--------|--------------|-------------------------|----------|-------------------------|
| 4 | Authors: P.G. | Vaughan-Shaw , | L.F. B | uijs ', J.P. | . Blackmur ', | A. Ewing | ΄, E. |

5 Theodoratou^{2,3}, Li-Yin. Ooi^{1,2,4} F.V.N. Din², S.M. Farrington², M.G. Dunlop^{1,2}

6

7 **Affiliations**:

- 8 ¹MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh,
- 9 Edinburgh, United Kingdom; ² Cancer Research UK Edinburgh Centre, Institute of Genetics
- 10 and Cancer, University of Edinburgh, Edinburgh, United Kingdom.³ Centre for Global Health
- 11 Research, Usher Institute for Population Health Sciences and Informatics, University of
- 12 Edinburgh, Edinburgh, United Kingdom.⁴ Department of Pathology, National University
- 13 Hospital, Singapore.
- 14

15 **Corresponding Author**:

- 16 Professor MG Dunlop. Institute of Genetics and Cancer, University of Edinburgh and MRC
- 17 Human Genetics Unit, Western General Hospital Edinburgh, Crewe Road, Edinburgh, EH4
- 18 2XU, United Kingdom. ORCID <u>0000-0002-3033-5851</u>; T: +44 (0)131 651 8500 E:
- 19 <u>malcolm.dunlop@ed.ac.uk</u>
- 20
- 21 Running title: Perioperative vitamin D supplementation in patients with colorectal cancer
- 22

23 Abbreviations

- 2425OHD25-hydroxyvitamin D25AJCCAmerican Joint Committee on Cancer stage
- 26 BMI Body mass index
- 27 CI Confidence interval
- 28 CRC Colorectal cancer
- 29 CRP C-reactive protein
- 30 SIR Systemic inflammatory response
- 31 SCOVIDS Scottish Vitamin D study
- 32 SOCCS Study of Colorectal Cancer in Scotland
- 33
- 34
- 35 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43 44
- 44 45
- 46

1 ABSTRACT

2

3 BACKGROUND

Post-operative vitamin D supplementation improves CRC survival outcomes in randomised
trials. The aim of this study was to test the feasibility, safety and efficacy of vitamin D in the
pre- and perioperative period in patients undergoing CRC surgery.

7

8 METHODS

9 Patients were given 3200IU oral cholecalciferol per day perioperatively. Serial serum
10 250HD was measured by liquid chromatography tandem mass spectrometry and compared to
11 untreated CRC controls. 250HD/CRP levels were compared using adjusted generalized
12 linear mixed-effects models.

13

14 **RESULTS**

15 122 patients underwent serial perioperative sampling, including 41 patients given high-dose 16 perioperative supplementation. 250HD was higher in patients given high-dose 17 supplementation compared to controls at all peri-operative timepoints (P<0.001) and 18 supplementation attenuated the post-operative drop in 25OHD (46% vs 24% drop). Rate of 19 vitamin D insufficiency was significantly less in those on supplementation (14% vs. 56%, 20 P=0.003), with multivariate modelling indicating a ~60nmol/l higher 25OHD compared to 21 control patients (P=1.22E-15). Supplementation was associated with lower peri-operative 22 CRP (P=0.035).

23

24 **DISCUSSIONS**

High dose pre-operative vitamin D supplementation is associated with higher perioperative
250HD levels, lower rates of vitamin D insufficiency and reduced early postoperative CRP.
These findings provide compelling rationale for early initiation of vitamin D supplementation
after a diagnosis of CRC.

- 29 30
- 31
- 32
- 33

1 ADDITIONAL INFORMATION

| 2 | Acknowledgements: We acknowledge the excellent technical support from Marion |
|----------|---|
| 3 | Walker and Stuart Reid. We are grateful to Donna Markie, and all those who continue to |
| 4 | contribute to recruitment, data collection, and data curation for the Study of Colorectal |
| 5 | Cancer in Scotland studies. We acknowledge the nursing and study facilities provided by |
| 6 | the Edinburgh Wellcome Trust Clinical Research Facility. Finally, we acknowledge that |
| 7 | these studies would not be possible without the patients and surgeons who take part. |
| 8 | The manuscript is available on medRxiv, MEDRXIV/2022/278022 |
| 9 | |
| 10 | Authors' contributions |
| 11 | Study concepts: PVS, LFB, JPB, LYO, FVND, SMF, MGD |
| 12 | Study design: PVS, LFB, LYO, JPB, ET, SMF, MGD |
| 13 | Data acquisition: PVS, LYO, LFB, JPB, |
| 14 | Quality control of data and algorithms: PVS, AE |
| 15 | Data analysis and interpretation: PVS, AE |
| 16 | Statistical analysis: PVS, AE |
| 17 | Manuscript preparation: PVS, LFB, JPB, AE, MT, SMF, MGD |
| 18 | Manuscript editing: PVS, LFB, JPB, AE, MT, SMF, MGD |
| 19 | Manuscript review: PVS, ET, AE, FVND, SMF, MGD |
| 20 | Funding acquisition: PVS, SMF, MGD |
| 21 | Project administration: MGD |
| 22 | Supervision: MGD, SMF |
| 23 | |
| 24 | Ethics approval and consent to participate: Participants provided informed written |
| 25 | consent, and research was approved by local research ethics committees (SOCCS |
| 26 | 11/SS/0109 and 01/0/05; SCOVIDS 13/SS/0248) and National Health Service |
| 27 | management (SOCCS 2013/0014, 2003/W/GEN/05; SCOVIDS 2014/0058). |
| 28 | |
| 29 | Consent for publication: Not applicable |
| 30 | |
| 31 | Data Availability Statement: Data available upon reasonable request |
| <u> </u> | 2 www. revenueshing survenience source and the point for source to prost |

32 **Competing interests:** The authors declare no potential conflicts of interest.

| 1 | Funding information: This work was supported by funding for the infrastructure and |
|----------|--|
| 2 | staffing of the Edinburgh CRUK Cancer Research Centre; CRUK programme grant |
| 3 | C348/A18927 (MGD). The study received a grant from Bowel Disease Research |
| 4 | Foundation (now Bowel Research UK). PVS was supported by a MRC Clinical Research |
| 5 | Training Fellowship (MR/M004007/1). LYO is supported by a Cancer Research UK |
| 6 | Research Training Fellowship (C10195/A12996). This work was also funded by a grant |
| 7 | to MGD as Project Leader with the MRC Human Genetics Unit Centre Grant |
| 8 | (U127527202 and U127527198 from 1/4/18). JB is supported by an Edinburgh Clinical |
| 9 | Academic Track (ECAT) linked Cancer Research UK Clinical Research Fellowship |
| 10 | (C157/A23218). |
| 11 | Role of the Funding Source: The funders had no role in design, undertaking, analysis or |
| 12 | writing of the above study. |
| 13 | |
| 14 | |
| 15 | |
| 16 | |
| 17 | |
| 18 | |
| 19 | |
| 20 | |
| 21 | |
| 22 | |
| 23 | |
| 24 | |
| 25 | |
| 26 | |
| 27 | |
| 28 | |
| 29 | |
| 30 21 | |
| 31 | |
| 33 | |
| 34 | |
| 35 | |
| 36 | |
| 37 | |
| 38 | |
| 39 | |

1 2 3 INTRODUCTION

4

5 Despite substantial improvement in mortality from colorectal cancer (CRC) over recent years, ~16,600 people die from CRC each year in the UK¹. Whilst surgery remains the 6 mainstay of therapy, new therapeutic approaches are required. Compelling evidence from 7 observational studies² demonstrate a link between low vitamin D and poor outcomes 8 following a diagnosis of colorectal cancer³⁻⁸, while a recent meta-analysis of trial data 9 10 demonstrating a 30% reduction in adverse CRC outcomes with supplementation⁹. Plasma 25-hydroxyvitamin D (250HD) levels in CRC patients are consistently lower than in 11 population controls ¹⁰, yet a key unanswered question is whether supplementation could 12 13 provide benefit from the time of diagnosis. Abdominal surgery is a major physiological insult 14 and 25OHD (the best marker and storage form of vitamin D) falls dramatically following 15 bowel cancer surgery². 25OHD is also known to decrease following orthopaedic, cardiac and gynaecological surgery ¹¹⁻¹⁶. Several explanations are proposed to explain the observed 16 decrease, including circulatory fluid changes i.e. haemodilution ^{14,17} and/or systemic 17 18 inflammatory responses to surgery. It follows that because 25OHD depletion is associated 19 with adverse survival outcomes and supplementation can improve survival, studies to define 20 when to initiate supplementation are required. While no study to date has assessed the impact 21 of vitamin D supplements in patients undergoing colorectal cancer resection, cholecalciferol 22 (vitamin D3) supplements have been shown to significantly improve 250HD levels in patients with a historical diagnosis of CRC¹⁸ and in patients undergoing chemotherapy for 23 CRC¹⁹. 24

Here, we have investigated the perioperative temporal variation in plasma 250HD and CRP by serially sampling patients undergoing CRC resectional surgery and aimed to demonstrate that vitamin D supplementation is feasible, safe and effective in the perioperative period. These data will be essential in informing the design of future randomised trials of vitamin D and survival outcomes after colorectal cancer surgery.

30

31 METHODS

32

The Study of Colorectal Cancer in Scotland (SOCCS) study is a national populationbased case-control study designed to identify genetic and environmental factors that have an impact on CRC risk and survival outcome ²⁰. The Scottish Vitamin D study (SCOVIDS) is a

1 single-centre study designed to investigate the link between vitamin D, CRC risk and 2 survival. Participants provided informed written consent, and research was approved by local 3 research ethics committees (SOCCS 11/SS/0109 and 01/0/05; SCOVIDS 13/SS/0248) and 4 National Health Service management (SOCCS 2013/0014, 2003/W/GEN/05; SCOVIDS 5 2014/0058) and registered with clinicaltrials.gov (NCT05506696). Clinical and sampling 6 variables were collected from patient case notes and pathology records, entered into a 7 prospective study database and extracted for analysis. We used data from patients recruited 8 between 2012 and 2013 who underwent serial sampling during the preoperative and immediate postoperative period, as previously described². We then recruited patients to 9 undergo high dose pre- and perioperative oral vitamin D supplementation (3200IU/ day 10 11 cholecalciferol, Fultium-D3, Internis Pharmaceuticals Ltd, Huddersfield, UK), alongside a 12 contemporaneous control group. All patients eligible for supplementation but not already 13 established on vitamin D or multivitamin supplementation were considered for inclusion 14 (Supplementary Table 1). Whether the patient was recruited by our research nurse, or surgical 15 research fellows (PVS/ LB) determined whether they were allocated to the control or 16 supplementation group respectively, itself determined by timetabling and clinic availability of 17 each recruiter. Patients administered supplementation took 3200IU everyday preoperatively, 18 including on the morning of surgery, and in the early postoperative period except where 19 postoperative ileus occurred. Given the pragmatic methodology, no alteration to the normal 20 patient pathway occurred and there was marked variation in duration of preoperative 21 supplementation between patients, in part due to delays and disruption from the COVID-19 22 pandemic. Recruitment was paused during the first wave of the COVID-19 pandemic, 23 significantly impacting on total study recruitment, while restrictions on hospital appointments 24 and non-clinical sampling limited the number of post-discharge samples that could be taken.

25

26 Plasma vitamin D assay

Samples were taken at preoperative assessment clinic and/or the day of surgery, and postoperatively (on the ward at 1-2 days, 3-5 days, 6-9 days) and at the first postoperative clinic appointment. COVID-19 restrictions and the emergency of telephone follow-up significantly impacted the ability to perform post-discharge sampling.

Plasma was extracted from blood sampled by venepuncture from a peripheral arm vein. To minimise any potential analytical variation in plasma 25OHD measurement, all samples were assayed in a single United Kingdom Accreditation Service (UKAS) accredited laboratory using a method traceable to National Standards of Science and Technology standard

reference material. 21 Total 25OHD (25OHD2 and 25OHD3) was measured by liquid
 chromatography tandem mass spectrometry and analysed using the Waters® Xevo® TQ-S
 system (Waters Limited, Wilmslow, UK).

4

5 Plasma CRP assay

6 To assess for potential relevance of the systemic inflammatory response, samples 7 were assayed for CRP in a NHS Biochemistry Laboratory serving our hospital. CRP was 8 measured using the Abbott Architect C series clinical chemistry analyser to standard 9 sensitivity protocol, with the range of output values 0.2-480 mg/l. CRP internal quality 10 control was performed daily, with 3 control samples assayed twice per day. Target mean of 11 the three control samples was 3.2, 8.3 and 27.5mg/l with actual observed mean over 6 months 12 of 3.2, 8.4 and 27.8mg/l respectively from 5151 completed assays. Coefficients of variation 13 were 3.42%, 2.34% and 2.05% respectively.

14

15 Sample size considerations

16 Data from our previously published control group ² was used to inform a power 17 calculation, with the current study design powered to identify a 50% suppression of the day 18 1-2 postoperative drop in 25OHD with supplementation (α =0.05 [one-tailed]; β =0.10, 19 calculated sample size in each arm = 54).

20

21 Patient and public involvement

This project is relevant to biomarker prediction and risk stratification and was assigned high priority in the seminal Association of Coloproctology of Great Britain and Ireland (ACPGBI) Delphi process ²². After draft protocol design, we developed our lay summary and PPI questionnaire in collaboration with the University of Edinburgh Patient Advisory Group and Patient Liaison Group of the ACPGBI. Thereafter we surveyed eight patients with colorectal cancer to assess the acceptability of the proposed serial sampling study and help inform our final study design.

29

30 Patient, Tumour and Treatment-Related Variables

We considered and adjusted for patient-related factors previously established to influence 25OHD levels (age, sex, body mass index (BMI). ²³⁻²⁵ Tumour and treatmentrelated variables were collected to investigate putative effect on 25OHD, including American

Joint Committee on Cancer (AJCC) stage. Information on tumour site, multiplicity and
 clinico-pathologic staging were obtained from clinical records, along with preoperative
 imaging. By using collated pathology, imaging, and clinical data; tumour stage was mapped
 onto the AJCC staging system (AJCC stage I to IV).

5

6 Statistical analysis

7 All statistical analysis was undertaken in R (version 4.1.0) [26]. To account for 8 seasonal differences in vitamin D status, reported 25OHD level was May-standardized by 9 adjusting for sampling month using differences in age- and sex-adjusted monthly averages 10 generated from SOCCS control data [27]. A linear mixed-effects model was applied to the 11 serially sampled data to examine the association between perioperative changes in CRP and 12 25OHD (log-transformed) and treatment group. This multivariable model adjusted for age, 13 gender, BMI and AJCC tumour stage. The package 'emmeans' was used to compute contrasts 14 between estimated marginal means to evaluate potential differences in 250HD between 15 treatment groups at each timepoint. Finally, a binomial generalized linear mixed-effects 16 model was applied to test for differences in rate of vitamin D insufficiency between treatment 17 groups and at each peri-operative timepoint, adjusting for age, gender, BMI and AJCC 18 tumour stage.

19

20 **RESULTS**

21 Baseline demographics

We recruited a total of 122 patients who underwent serial perioperative sampling at up to 6 time-points, including 41 patients who received high-dose perioperative vitamin D supplementation (Table 1). No significant differences in baseline clinicopathological variables between the groups were observed. No differences between the previously published control group and newly recruited control group were observed, including in baseline 25OHD (46.3 *vs.* 47.6nmol/l, P=0.86; Supplementary Table 2).

28

29 Efficacy and safety of perioperative supplementation

No serious adverse events occurred in those taking perioperative supplementation, which was well tolerated in study participants. In patients with both a pre- and postsupplementation sample (N=13), supplementation induced a 2.1 fold-increase (48.2nmol/; 95%CI 20.7-75.6; P=0.01) in 25OHD level (Table 2, Figure 1). Overall, patients took preoperative supplementation for median 25 days (range 9-84) with no correlation between

number of days' supplementation and either increase in 25OHD (R=-0.20, P=0.5) or 25OHD
level on day of surgery (R=0.14, P=0.39). Dose diaries assessed for 8 subjects, indicated high
compliance with daily supplementation (316 out of 319 days perioperative supplementation
completed).

5 Supplemented patients had higher 25OHD levels on the day of surgery (P=8.2E-12, 6 Table 2) and in the early postoperative period when compared to control patients (e.g. 1-2) 7 days 80.9nmol/l vs. 26.7nmol/l, P=3.6E-15; Table 2, Figure 1). Crucially, the multivariate 8 fixed-effects model confirmed a significant and clinically relevant impact of supplementation 9 on perioperative 25OHD levels, after adjusting for age, gender, BMI and AJCC stage (Table 10 2; Supplementary Table 3). Supplementation also reduced the prevalence of perioperative 11 vitamin D insufficiency (250HD<50nmol/l), with 14% of supplemented patients having 12 early postoperative insufficiency compared to 56% of control patients (P=0.003, Table 4). 13 Finally, although 25OHD levels dropped in all treatment groups following surgery, 14 supplementation attenuated the early post-operative drop (e.g. 46% drop vs. 24% drop at days 15 1-2, P=0.0003). (Figure 1; Supplementary Table 4).

- 16
- 17

Impact of supplementation on postoperative CRP levels

18 CRP levels assayed at the same time as 25OHD were compared across treatment 19 groups. As expected, CRP increased postoperatively in all groups, yet the increase appeared 20 less in those taking high-dose supplementation, with lower early postoperative CRP levels 21 seen in these patients (e.g. 3-5 days 80.5mg/l *vs.* 129mg/l, P=0.04, Table 5, Supplementary 22 Figure 2). The multivariate mixed-effects model indicated that supplementation had a 23 modest impact on peri-operative CRP levels after adjusting for age, gender, BMI and AJCC 24 stage (P=0.035; Table 3; Supplementary Table 5).

25

26 **DISCUSSION**

High-dose perioperative vitamin D supplementation is safe and well tolerated in patients undergoing colorectal cancer surgery. Compared to control patients, supplementation induces a significant increase in perioperative 25OHD levels, a smaller relative drop in 25OHD following surgery and lower rates of postoperative vitamin D insufficiency. Meanwhile, early postoperative CRP appears to lower in patients on supplementation supporting the role of vitamin D in regulation of inflammatory processes.

1 This study provides evidence for a beneficial effect of vitamin D supplementation on 2 perioperative vitamin D status while a recent meta-analysis of RCT data reported a significant reduction in CRC mortality with vitamin D supplementation ^{9,26}. Taken together, 3 4 these data support early initiation of supplementation at the point of CRC diagnosis. While 5 vitamin D repletion has already been shown to be feasible in patients undergoing chemotherapy ^{3,4,19}, no study to date has explored its use in CRC patients in the perioperative 6 period. Vitamin D levels are known to drop following surgery 2 , which is confirmed here in 7 8 all treatment groups. Here, we demonstrate that despite the insult of resectional cancer 9 surgery, and associated changes in gut motility and absorption, perioperative supplementation 10 induces a marked increase in preoperative 250HD levels and attenuates the drop in 250HD 11 following surgery. Given the tight physiological autoregulation that exists, it is unlikely that 12 mechanisms that confer the observed beneficial impact of vitamin D on CRC survival occur 13 in a linear manner, but rather that a threshold effect exists. Given that our previous work 14 suggests that a 25OHD threshold of ~45-50nmol/l appears to most strongly associate with 15 survival, it is relevant that in the current study supplementation significantly reduced 16 postoperative vitamin D insufficiency (250HD<50nmol/l).

17 To date, no trial has investigated the optimum time to initiate supplementation. 18 Indeed, few of the supplementation trials in CRC patients include patients undergoing 19 curative resection, with one such trial (AMATERASU trial), recruiting patients at the first outpatient visit after surgery ⁵. It is relevant that in population trials where recruitment and 20 21 supplementation occur before the diagnosis of incident cases of CRC, a beneficial effect of 22 vitamin D supplementation on survival is still seen. Furthermore, 25OHD levels sampled 23 preoperatively and at the earliest postoperative timepoint (<6 months) are already associated 24 with survival in observational data 2 . Therefore, given that this cheap supplement has now 25 been shown to be safe and well tolerated in the perioperative period, there is compelling 26 rationale to start at the point of diagnosis, especially given the increasing use of neo-adjuvant 27 therapy which can delay resectional CRC surgery for many months.

Previous pre-clinical and human intervention studies provide clues to the mechanisms that may underlie the beneficial effect of supplementation on CRC survival and provide no contra-indication to earlier supplementation. 1,25-dihydroxyvitamin D3 modulates immune and inflammatory pathway genes in large bowel epithelium ²⁷ while oral supplementation induces transcriptomic changes in rectal mucosa that are linked to anti-tumour effects ²⁸. Vitamin D also regulates multiple inflammatory processes both *in vitro* and *in vivo*, including those involved in CRC such as oxidative stress and the cyclooxygenase and NF-kB pathways

1 ^{29,30}. Effects on inflammatory processes are consistent with the lower postoperative CRP2 levels in supplemented patients in the current study, supporting the notion that vitamin D3 might be causally implicated in the SIR response following surgery. This provides further4 potential mechanism to improved survival outcomes with supplementation given that CRP,5 an established marker of inflammation, is strongly correlated with CRC survival ^{31,32}.

6 The current study has a number of limitations. We acknowledge that supplemented 7 patients recruited in 2020 were compared against a combined control group including 8 patients recruited in 2013. As such, unmeasured historical differences in demographics, genetic background (e.g. vitamin D receptor or pathway SNPs³³) or clinical factors may 9 confound the observed effect of supplementation. However, we observed no difference in 10 11 baseline or peri-operative 25OHD between the two control groups. Furthermore, mixed-12 modelling identified a significant association between supplementation and increased 25OHD 13 level when comparing supplemented patients with the newest control cohort (~60nmol/l; 14 P=3.51E-08). Nevertheless, we cannot fully exclude the possibility that differences in 15 perioperative 25OHD levels are due to factors other than supplementation (i.e. confounding 16 factors) because this was not a randomised study. Third, the power of our study was limited 17 by COVID-19 which markedly impacted total study recruitment and sampling. Finally, while 18 our data supports the early initiation of supplementation in patients undergoing CRC surgery 19 given its effects on 25OHD level and extrapolating from previous trial evidence of survival 20 benefit, we do not provide direct evidence of survival benefit from early supplementation.

21 In conclusion, we report for the first time on the feasibility and safety of perioperative 22 vitamin D supplementation in patients undergoing colorectal cancer surgery. We identified a 23 positive effect of supplementation on perioperative 25OHD levels with lower rates of 24 postoperative vitamin D insufficiency and reduced early postoperative CRP. Our findings 25 provide compelling rationale for early initiation of vitamin D supplementation after a 26 diagnosis of CRC. Future randomised trials of supplementation with a defined endpoint of a 27 beneficial effect on survival outcomes should consider supplementation from the point of 28 diagnosis.

29

30

31 **References**

32

CRUK. Cancer statistics. <u>https://www.cancerresearchuk.org/health-</u>
 professional/cancer-statistics/statistics-by-cancer-type. Accessed 24/12/2019, 2019
 (2019).

Vaughan-Shaw PG, Zgaga L, Ooi LY, Theodoratou E, Timofeeva M, Svinti V *et al.* Low plasma vitamin D is associated with adverse colorectal cancer survival after
 surgical resection, independent of systemic inflammatory response. *Gut* 2020; 69(1):
 103-111; e-pub ahead of print 2019/04/27; doi 10.1136/gutjnl-2018-317922.

- Antunac Golubic Z, Barsic I, Librenjak N, Plestina S. Vitamin D Supplementation
 and Survival in Metastatic Colorectal Cancer. *Nutr Cancer* 2018; **70**(3): 413-417; epub ahead of print 2018/03/14; doi 10.1080/01635581.2018.1445766.
- 8 4. Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM *et al.* Effect
 9 of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free
 10 Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The
 11 SUNSHINE Randomized Clinical Trial. *JAMA* 2019; **321**(14): 1370-1379; e-pub
 12 ahead of print 2019/04/10; doi 10.1001/jama.2019.2402.
- 13 5. Urashima M, Ohdaira H, Akutsu T, Okada S, Yoshida M, Kitajima M et al. Effect of 14 Vitamin D Supplementation on Relapse-Free Survival Among Patients With 15 Digestive Tract Cancers: The AMATERASU Randomized Clinical Trial. JAMA 16 2019; **321**(14): 1361-1369; e-pub ahead of print 2019/04/10; doi 17 10.1001/jama.2019.2210.
- 18 6. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3
 19 (cholecalciferol) supplementation on fractures and mortality in men and women living
 20 in the community: randomised double blind controlled trial. *BMJ* 2003; **326**(7387):
 21 469; e-pub ahead of print 2003/03/01; doi 10.1136/bmj.326.7387.469

22 326/7387/469 [pii].

- Manson JE, Bassuk SS, Buring JE, Group VR. Principal results of the VITamin D and
 OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. J
 Steroid Biochem Mol Biol 2019; 198: 105522; e-pub ahead of print 2019/11/17; doi
 10.1016/j.jsbmb.2019.105522.
- Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan
 MJ *et al.* Calcium plus vitamin D supplementation and the risk of colorectal cancer. *N Engl J Med* 2006; **354**(7): 684-696; e-pub ahead of print 2006/02/17; doi 354/7/684
 [pii]

31 10.1056/NEJMoa055222.

- 9. Vaughan-Shaw PG, Buijs LF, Blackmur JP, Theodoratou E, Zgaga L, Din FVN *et al.*The effect of vitamin D supplementation on survival in patients with colorectal
 cancer: systematic review and meta-analysis of randomised controlled trials. *Br J Cancer* 2020; e-pub ahead of print 2020/09/16; doi 10.1038/s41416-020-01060-8.
- Theodoratou E, Palmer T, Zgaga L, Farrington SM, McKeigue P, Din FV *et al.*Instrumental variable estimation of the causal effect of plasma 25-hydroxy-vitamin D
 on colorectal cancer risk: a mendelian randomization analysis. *PLoS One* 2012; 7(6):
 e37662; e-pub ahead of print 2012/06/16; doi 10.1371/journal.pone.0037662

40 PONE-D-11-23990 [pii].

- Skuladottir GV, Cohen A, Arnar DO, Hougaard DM, Torfason B, Palsson R *et al.*Plasma 25-hydroxyvitamin D2 and D3 levels and incidence of postoperative atrial
 fibrillation. *J Nutr Sci* 2016; **5**: e10; doi 10.1017/jns.2015.38.
- Pilka R, Marek R, Adam T, Kudela M, Ondrova D, Neubert D *et al.* Systemic
 Inflammatory Response After Open, Laparoscopic and Robotic Surgery in
 Endometrial Cancer Patients. *Anticancer Res* 2016; **36**(6): 2909-2922.
- Louw JA, Werbeck A, Louw ME, Kotze TJ, Cooper R, Labadarios D. Blood vitamin
 concentrations during the acute-phase response. *Crit Care Med* 1992; **20**(7): 934-941.
- McNally JD, Menon K, Chakraborty P, Fisher L, Williams KA, Al-Dirbashi OY *et al.* Impact of anesthesia and surgery for congenital heart disease on the vitamin d status

| 1 | | of infants and children: a prospective longitudinal study. Anesthesiology 2013; |
|-----------------|--------|--|
| 2 | 1.5 | 119 (1): /1-80; doi 10.109//ALN.0b013e31828ce81/. |
| 3 | 15. | Reid D, Toole BJ, Knox S, Talwar D, Harten J, O'Reilly DS et al. The relation |
| 4 | | between acute changes in the systemic inflammatory response and plasma 25- |
| 5 | | hydroxyvitamin D concentrations after elective knee arthroplasty. Am J Clin Nutr |
| 6 | | 2011; 93 (5): 1006-1011; doi 10.3945/ajcn.110.008490. |
| 7 | 16. | Waldron JL, Ashby HL, Cornes MP, Bechervaise J, Razavi C, Thomas OL et al. |
| 8 | | Vitamin D: a negative acute phase reactant. J Clin Pathol 2013; 66(7): 620-622; doi |
| 9 | | 10.1136/jclinpath-2012-201301. |
| 10 | 17. | Krishnan A, Ochola J, Mundy J, Jones M, Kruger P, Duncan E et al. Acute fluid |
| 11 | | shifts influence the assessment of serum vitamin D status in critically ill patients. Crit |
| 12 | | <i>Care</i> 2010; 14 (6): R216; doi 10.1186/cc9341. |
| 13 | 18. | Vaughan-Shaw P.G. OLY, Timofeeva M., Svinti V., Walker M., Farrington S.M., Din |
| 14 | | F.V., Dunlop M.G. Peri-operative plasma vitamin D level in colorectal cancer patients |
| 15 | | and effect of vitamin D supplementation on colorectal cancer patients. Colorectal |
| 16 | | disease : the official journal of the Association of Coloproctology of Great Britain |
| 17 | | and Ireland 2016: 18 (Supp 2): 34. |
| 18 | 19. | Savoie MB. Paciorek A. Zhang L. Van Blarigan EL. Sommovilla N. Abrams D <i>et al.</i> |
| 19 | -,. | Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment |
| 20 | | Initiation I Gastrointest Cancer 2019: 50(4): 769-779: e-pub ahead of print |
| 21 | | 2018/07/31· doi 10 1007/s12029-018-0147-7 |
| 22 | 20 | Theodoratou F Kyle I Cetnarsky R Farrington SM Tenesa A Barnetson R et al |
| $\frac{22}{23}$ | 20. | Dietary flavonoids and the risk of colorectal cancer <i>Cancer Epidemiol Biomarkers</i> |
| $\frac{23}{24}$ | | Prev 2007: 16(4): $684-693$: e-nub abead of print 2007/04/10: doi 16/4/684 [nii] |
| 25 | 10 115 | 8/1055-9965 FPI-06-0785 |
| 25 | 21 | Knox S Harris I Calton I Wallace AM A simple automated solid-phase extraction |
| 20 | 21. | procedure for measurement of 25-hydroxyvitamin D3 and D2 by liquid |
| 28 | | chromatography-tandem mass spectrometry Ann Clin Riochem 2009: 46(Pt 3): 226- |
| 29 | | 230; doi 10.1258/acb.2009.008206. |
| 30 | 22. | Tiernan J, Cook A, Geh I, George B, Magill L, Northover J et al. Use of a modified |
| 31 | | Delphi approach to develop research priorities for the association of coloproctology of |
| 32 | | Great Britain and Ireland. Colorectal Dis 2014: 16(12): 965-970: e-pub ahead of print |
| 33 | | 2014/10/07: doi 10.1111/codi.12790. |
| 34 | 23 | Kimlin MG Lucas RM Harrison SL van der Mei L Armstrong BK Whiteman DC et |
| 35 | 20. | al The contributions of solar ultraviolet radiation exposure and other determinants to |
| 36 | | serum 25-hydroxyvitamin D concentrations in Australian adults: the AusD Study Am |
| 37 | | <i>LEnidemiol</i> 2014: 179 (7): 864-874: e-pub ahead of print $2014/02/28$: doi kwt446 [pii] |
| 38 | 10 109 | 3/aie/kwt446 |
| 39 | 24 | Mithal A Wahl DA Boniour IP Burckhardt P Dawson-Hughes B Fisman IA et al. |
| 40 | 27, | Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int 2009: |
| 40 | | 20 (11): $1807-1820$: doi 10.1007/s00198-009-0954-6 |
| 41 1 | 25 | Zgaga I. Theodoratou F. Farrington SM. Din EV. Ooi I.V. Glodzik D. et al. Plasma |
| 72 //3 | 23. | vitamin D concentration influences survival outcome after a diagnosis of coloractal |
| 43 | | capeer I Clin Oncol 2014: 32 (23): 2430-2430: doi: 10.1200/ICO.2013.54.5947 |
| 44 15 | 26 | Koum N. Lee DH. Greenwood DC. Manson JE. Giovannucci E. Vitamin D. |
| 45 | 20. | supplementation and total cancer incidence and mortality: a mate analysis of |
| 40 17 | | randomized controlled trials Ann Oncol 2010: 20(5): 722 742: a pub sheed of print |
| +/ /8 | | randomized controlled thats. Ann Oncol 2019, $50(5)$. 755-745, e-pub allead of print $2010/02/24$: doi 10.1003/appone/mdz050 |
| +0 40 | 27 | Drotive D Dandvele S Nelson C Augenlight I U Linkin M Helt DD Coleium and |
| +7 50 | 21. | 1.25 dihydroyygitamin D3 modulate genes of immune and inflammatory nethogenesis |
| 50 | | 1,25-anyaroxy mannin D5 modulate genes of minimute and innaminatory pattways in |

| 1 | | the human colony a human procession trial Arry I Clin Nutr 2016, 102(5), 1224 1221. |
|--------|-----|---|
| 1 | | doi 10.3045/ajon 114.105304 |
| 23 | 28 | Vaughan-Shaw PG, Grimes G, Blackmur IP, Timofeeva M, Walker M, Ooi I V et al. |
| 1 | 20. | Oral vitamin D supplementation induces transcriptomic changes in rectal mucosa that |
| - - | | are linked to anti tumour affects. BMC Med 2021: 10(1): 174: a pub about of print |
| 6 | | 2021/08/04 · doi 10 1186/s12916-021-02044-y |
| 7 | 20 | van Harten-Gerritsen AS Balvers MG Witkamp RE Kampman E van Dujinhoven |
| 8 | 27. | FI Vitamin D Inflammation and Colorectal Cancer Progression: A Review of |
| 9 | | Mechanistic Studies and Future Directions for Enidemiological Studies <i>Cancer</i> |
| 10 | | <i>Enidemiol Biomarkers Prev</i> 2015: 24(12): 1820-1828: doi 10.1158/1055-9965 EPI- |
| 11 | | 15-0601. |
| 12 | 30. | Bostick RM. Effects of supplemental vitamin D and calcium on normal colon tissue |
| 13 | | and circulating biomarkers of risk for colorectal neoplasms. The Journal of steroid |
| 14 | | biochemistry and molecular biology 2015; 148: 86-95; doi |
| 15 | | 10.1016/j.jsbmb.2015.01.010. |
| 16 | 31. | McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts |
| 17 | | survival following curative resection of colorectal cancer. Br J Surg 2003; 90(2): 215- |
| 18 | | 219; doi 10.1002/bjs.4038. |
| 19 | 32. | McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade |
| 20 | | of experience in patients with cancer. Cancer Treat Rev 2013; 39(5): 534-540; doi |
| 21 | | 10.1016/j.ctrv.2012.08.003. |
| 22 | 33. | Revez JA, Lin T, Qiao Z, Xue A, Holtz Y, Zhu Z et al. Genome-wide association |
| 23 | | study identifies 143 loci associated with 25 hydroxyvitamin D concentration. Nat |
| 24 | | Commun 2020; 11(1): 1647; e-pub ahead of print 2020/04/04; doi 10.1038/s41467- |
| 25 | | 020-15421-7. |
| 26 | | |



Treatment



Control

VitD

| | Control | VitD | P† |
|---------------------------------|-------------|---------------|-------------|
| N | 81 | 41 | - |
| Sampling Years | 2013-2020 | 2020 | - |
| Age (years, SD) | 66.4 (13.0) | 64.7 (14.1) | 0.72 |
| Gender (F) | 37 (46%) | 17 (41%) | 0.70 |
| BMI (kg/m ² , SD) | 27.0 (4.4) | 28.5 (5.7) | 0.11 |
| Baseline 25OHD (median, IQR) | 42.5 (31.9) | 50.49 (27.79) | 0.35 |
| Cancer site | | | - |
| Colon | 49 (60%) | 17 (41%) | 0.06 |
| Rectum | 32 (40%) | 24 (59%) | 0.06 |
| Cancer stage | | | |
| AJCC 1 | 26 (32%) | 8* (21%) | |
| AJCC 2 | 27 (33%) | 12 (32%) | |
| AJCC 3 | 19 (23%) | 17 (45%) | |
| AJCC 4 | 9 (11%) | 1 (3%) | Ptrend=0.74 |

TABLE 1 Clinicopathological demographics of included patients

*3 additional patients who underwent neo-adjuvant therapy classified as ypT0 on histological analysis.

TABLE 2 May-adjusted perioperative 250HD

| | Control | | High-dose VitD | | | |
|-------------|---------|-------------|----------------|--------------|---------|----------|
| | Ν | 25OHD | Ν | 25OHD | P† | P* |
| Clinic | - | - | 13 | 50.5 (27.8) | NA | NA |
| Pre-op | 81 | 42.5 (31.9) | 40 | 103.9 (49.5) | 8.2E-12 | 3.34E-15 |
| 1-2 days | 81 | 26.7 (20.7) | 41 | 80.9 (39.6) | 3.6E-15 | 3.27E-23 |
| 3-5 days | 77 | 28.5 (22.3) | 38 | 92.9 (33.9) | 2.9E-13 | 8.69E-23 |
| 6-9 days | 60 | 28 (26.6) | 22 | 82.5 (36.2) | 1.1E-06 | 6.53E-12 |
| 30-120 days | 61 | 34.2 (21.5) | 15 | 112 (31.2) | 9.4E-08 | 1.75E-16 |

Median 250HD levels given in nmol/l with IQR. † univariate P value. *FDR P value given adjusted in fixed effects model for gender, AGE, BMI and AJCC

TABLE 3 Impact of treatment on 250HD and CRP levels in mixed-effects model

| | May-adjusted 25OHD | CRP | | | | | |
|---------------|----------------------|----------|--|--|--|--|--|
| Univariate mo | Univariate model | | | | | | |
| Estimate | 60.4nmol/l | 2mg/l | | | | | |
| Р | 2.77e-14 | 0.045 | | | | | |
| Fully adjuste | Fully adjusted model | | | | | | |
| Estimate | 62.2nmol/l | 2.59mg/l | | | | | |
| Р | 1.22e-15 | 0.035 | | | | | |

Adjusted model included age, gender, BMI and AJCC

| TABLE 4 | Perioperative | Vitamin D |
|---------|---------------|-----------|
|---------|---------------|-----------|

| Timepoint | Control | High-dose VitD | | |
|-------------|----------|-------------------|----------|----------|
| | N (%) | N (%) | P† | P* |
| Clinic | 55 (68%) | 3 (8%) | 3.06E-09 | 3.04E-07 |
| Pre-op | 69 (86%) | 11 (28%) | 8.2E-12 | 1.34E-07 |
| 1-2 days | 64 (84%) | 5 (14%) | 3.6E-15 | 1.39E-08 |
| 3-5 days | 52 (87%) | 4 (20%) | 2.9E-13 | 1.40E-06 |
| 6-9 days | 55 (68%) | 3 (8%) | 1.1E-06 | 3.66E-06 |
| 30-120 days | 69 (86%) | 11 (28%) | 9.4E-08 | 3.04E-07 |

Vitamin D insufficiency <50nmol/l. † univariate P value. *FDR P value given adjusted in fixed effects model for gender, AGE, BMI and AJCC.

| TABLE 5 Periopera | ative CRP levels | in control and | supplemented | patients |
|--------------------------|------------------|----------------|--------------|----------|
|--------------------------|------------------|----------------|--------------|----------|

| Control | | VitD | | | | |
|-----------|----|-----------------|----|-----------------|-------|------------|
| Timepoint | Ν | CRP (mg/l, iqr) | N | CRP (mg/l, iqr) | P† | P * |
| Pre-op | 59 | 5 (11) | 38 | 3 (9) | 0.16 | 0.04 |
| 1-2 days | 58 | 97.5 (62.25) | 39 | 78 (48) | 0.049 | 0.33 |
| 3-5 days | 57 | 129 (121) | 39 | 81 (72.6) | 0.017 | 0.04 |
| 6-9 days | 46 | 61 (58) | 18 | 54 (75) | 0.95 | 0.90 |

Median CRP levels given in mg/l with IQR. † univariate P value. *FDR P value given adjusted in fixed effects model for gender, AGE, BMI and AJCC